Clinical Trials Logo

Filter by:
NCT ID: NCT04791722 Completed - Smoking Cessation Clinical Trials

Optimizing Smoke-free Residential Housing Policies

Start date: May 20, 2019
Phase: N/A
Study type: Interventional

This project will be conducted to investigate activities on housing-related health and safety issues. The focus of this project is the development of evidence-based approaches to implement smoke-free policies to reduce harms associated with exposure to secondhand smoke (SHS).

NCT ID: NCT04790903 Completed - Clinical trials for Lymphoma, Large B-Cell, Diffuse

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Start date: July 2, 2021
Phase: Phase 1
Study type: Interventional

This Phase Ib, open-label, multicenter study evaluates the safety, efficacy, and pharmacokinetics of venetoclax in combination with Pola + R-CHP in previously untreated participants with BCL-2 IHC-positive DLBCL. Approximately 50 participants will be enrolled in this study in five consecutive cohorts each consisting of approximately 10 participants.

NCT ID: NCT04790812 Completed - Pain, Postoperative Clinical Trials

Preemptive Analgesia With Celecoxib for Acute Dental Pain Management

Start date: April 22, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effect on postoperative pain of a single agent nonsteroidal anti-inflammatory drug (NSAID) [celecoxib plus placebo] to an NSAID combination [celecoxib plus acetaminophen] administered preemptively to patients prior to impacted third molar surgery. .

NCT ID: NCT04790552 Completed - Fasting Clinical Trials

Effects of Fast Bar on Intermittent Fasting

FastBar2
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This study evaluates how Fast Bar(TM), a specially formulated energy bar, when consumed with coffee or tea, affects the physiological condition in participants after an overnight fasting. Participants will fast for 19 hours (Fast Group), consume a Fast Bar in the night (Night Bar Group) or in the morning (Bar+Coffee and Bar+Tea Groups) after an approximately 15-hour overnight fasting. Participants will be assessed for physiological parameters associated with fasting.

NCT ID: NCT04790513 Completed - Clinical trials for Cardiovascular Diseases

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

LIBerate-H2H
Start date: April 22, 2021
Phase: Phase 3
Study type: Interventional

Comparison of LDL-C reductions at Week 12 of monthly (Q4W[≤ 31 days]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and other LDL-C-lowering drug therapy.

NCT ID: NCT04790279 Completed - Clinical trials for Hypertension in Pregnancy

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Start date: April 9, 2021
Phase: Phase 4
Study type: Interventional

A significant number of pregnancies are complicated by hypertensive disorders. Hypertension often worsens in the postpartum period and many women need started on medications. Currently, recommended medications for blood pressure management in pregnant and postpartum women are limited, with labetalol and nifedipine ER being the most commonly used medications. While these medications are both effective, they are not without limitations. Amlodipine is a medication in the same class as nifedipine ER. It is a first-line antihypertensive in the general population. It tends to have less side effects than nifedipine ER. It has not been studied specifically in postpartum women. The purpose of this study is to determine if amlodipine is noninferior to nifedipine ER in managing hypertension in the postpartum period.

NCT ID: NCT04789668 Completed - Metastatic Melanoma Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Start date: January 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases). Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of the monoclonal antibody anti-PD-L1 and TGF-beta, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pimasertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pimasertib and bintrafusp alfa may help to prevent or delay the cancer from progressing (getting worse) and/or coming back.

NCT ID: NCT04789577 Completed - Influenza, Human Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Start date: March 16, 2021
Phase: Phase 2
Study type: Interventional

Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.

NCT ID: NCT04789499 Completed - Covid19 Clinical Trials

Smell in Covid-19 and Efficacy of Nasal Theophylline

SCENT2
Start date: March 15, 2021
Phase: Phase 2
Study type: Interventional

Evidence of COVID-19 related anosmia and dysgeusia continues to accumulate daily. Currently, up to 80% of patients report subjective olfactory dysfunction (OD), and prevalence using objective olfactory testing could be even higher. We propose a phase II single-site, double-blinded, placebo-controlled randomized clinical trial to determine the efficacy and safety of intranasal theophylline, a known phosphodiesterase inhibitor in the treatment of asthma, as a possible treatment for COVID-19 related OD. Theophylline has shown benefit in similar clinical trials for post-viral OD.

NCT ID: NCT04789382 Completed - Refractive Errors Clinical Trials

Three Daily Wear Monthly Replacement Silicone Hydrogel Contact Lenses With Two Multi-purpose Disinfecting Solution Combinations

Start date: April 7, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate corneal staining observed after 2 hours of wear with an investigational contact lens against both PureVision contact lenses pre-cycled with Biotrue and Biofinity contact lenses pre-cycled with RepleniSH.